1Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222. 被引量：1
2Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027. 被引量：1
3Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690. 被引量：1
4Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888. 被引量：1
5Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542. 被引量：1
6Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281. 被引量：1
7Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104. 被引量：1
8Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493. 被引量：1
9O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406. 被引量：1
10O'Reilly SM,Moiseyenko V,Talbot DC, et al. A randomized phase Ⅱ study of Xeloda (capecitabine)vs paclitaxel in breast cancer patients failing previous anthracycline therapy[J]. Proc Am Soc Clin Oncol, 1998,17: 627-635. 被引量：1
